Introduction
Various techniques have been developed to express recombinant constructs within cells, in culture, in animal models and in humans. 1 The application of molecular genetics to human biology and disease has improved our understanding of and ability to treat a variety of disease states. Retroviral gene delivery vectors based on oncoretroviruses, such as Moloney murine leukemia virus (MLV), have been the most commonly used vectors for gene transfer into the host cell genome. 2, 3 MLV has been used to deliver therapies for diverse diseases, including cancer, inherited genetic disorders and infection with HIV-1. However, onco-retroviral vectors have limitations that often include a need to select cultured cells to enrich for those cells expressing the transgene. Such selection generally necessitates transduction ex vivo, followed by cumbersome selection in culture.
We have devised a gene transfer system based on simian virus-40 (SV40) as a vector. 4 SV40 infects a wide range of cell types from humans and other mammals and expresses its genes in them. Recombinant, replicationdeficient SV40-derived vectors may express transgenes stably in cell lines, in primary cultures, and in vivo. [4] [5] [6] The virus is stable to manipulation and can be made to high titer (у10 10 infectious units (IU)/ml), and further concentrated if needed.
HIV-1, as a member of the lentivirus family, has a complex viral life cycle and utilizes multiple cellular and virally encoded regulatory proteins to tightly control its replication. 7 The essential retroviral enzymes, reverse transcriptase (RT), ribonuclease H (RNaseH), protease (PR) and integrase (IN), lack cellular counterparts and have been used as targets for developing agents that inhibit virus replication. [8] [9] [10] Despite considerable advances in anti-RT and PR chemotherapy, genetic changes in the virus can confer drug resistance. 11 This problem has led to proposals for alternative therapeutic strategies in which host cells may be genetically altered or engineered to confer long-lasting protection against virus infection or replication. 12, 13 Several such strategies are currently being reported and applied to the inhibition of HIV-1 replication. They include exploitation of transdominant-negative mutant HIV-1 protein expression, viral antisense oligonucleotide sequences, specific ribozymes, HIV-1 transactivated suicide genes and intracellular antibodies against several different HIV-1-specific proteins. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Recently, we reported that intracellular expression of SFv moieties targeted to RT, IN and Rev strongly inhibited HIV-1 replication in human cells. [15] [16] [17] [18] [19] [20] 23, 24, 27 An early event in the life cycle of all retroviruses, including HIV-1, is integration of a double-stranded proviral DNA into the host cell genome. This step is necessary for productive viral replication. 28 In natural infection, linear viral DNA contained within pre-integration complexes is the direct precursor of the integrated proviral genome. 29 In previous studies, we demonstrated that anti-IN SFv #33, driven by the cytomegalovirus immediate-early promoter (CMV-IEP) and delivered by MLV to selected human T-lymphocytes, effectively inhibited HIV-1 replication. 20 To assess intracellular immunization as a tool for gene therapy of HIV-1 infection further, IN was targeted for specific blockade by the same anti-IN intracellular SFv expression construct, but delivered using an SV40 vector. The effectiveness of this construct in inhibiting HIV-1 was tested in a CD4
+ human T lymphoma cell line. We show here that an SV40-derived vector can transduce human T-lymphocytic cells to express the protein SFv-IN effectively without selection. Furthermore, HIV-1 replication, as measured by HIV-1 p24 antigen expression and syncytia formation, was inhibited in SupT1 T-lymphocytic cells expressing SFv-IN.
Results

Construction of viruses expressing SFvIN#33 and HBsAg proteins
A map of SV(HBS) has been reported. 30 This recombinant SV40 virus was used as a negative control. Construction of pSLXCMV-SFvIN#33, which expresses SFvIN#33, has been described previously. 20 Briefly, sequences encoding the variable light (V 1 ) and variable heavy (V h ) chains of the anti-IN monoclonal antibody (Mab) were cloned from a murine hybridoma cell-line's RNA. After ligation of V 1 and V h chains into a single fragment, by utilizing the flexible linker (GGGGS) 3 , the SFv fragment was cloned into an SV40 expression vector downstream of cytomegalovirus immediate-early promoter (CMV-IEP). The orientations and structures of open reading frames were verified by DNA sequencing. A map of the SV40 vector containing the SFvIN#33 (SV(Aw)) driven by CMV-IEP, and used for all these studies, is shown in Figure 1 .
Detection of SFvIN#33 by Western blotting
Lysates were prepared from 10 6 SupT1 cells transduced as described with SV(Aw) or with MLV-SFvIN#33, or mock-transduced. These proteins were electrophoresed using SDS-PAGE, blotted to PVDF membranes, probed with anti-mouse IgG antibody and visualized as described in Materials and methods. As a positive control, recombinant SFvIN#33 produced in E. coli was used. Results demonstrated that both selected MLV-SFvIN#33-transduced SupT1 cells and unselected SV(Aw)-transduced cells expressed the SFvIN#33 transgene ( Figure 2) . Levels of transgene expression were comparable in unselected SV(Aw)-transduced cells and in selected MLV-SFvIN#33-transduced cells (Figure 2 ). The larger molecular size bands seen here in the extracts from 
SV40 delivery of SFvIN#33 and expression in mammalian cells
To obtain transfectants expressing SFvIN#33 and HBsAg, recombinant SV40-based viruses were prepared from COS-7 packaging cells and SupT1 cells were treated with these viruses as described in Materials and methods. After infection with SV(Aw) or SV(HBS), the cells were cultured for 2 weeks without selection and then analyzed by immunostaining. Expression of SFvIN#33 was detected using an anti-mouse IgG. The SV(Aw)-treated SupT1 cells express the transgene, SFvIN#33 (Figure 3 ). SupT1 cells treated with SV(HBS) were used as controls and did not express detectable SFvIN#33 (Figure 3 ). The anti-IN-SFv protein was principally detected in the cytoplasm of transduced cells.
These results are important for several reasons. First, these data demonstrate that SV40 can transduce SupT1 cells to express the anti-IN SFv efficiently. Secondly, the efficiency of SV40 transduction is very high: more than 90% of cells stain positively for SFvIN#33 expression. Unlike our experience with MLV transduction of the same SFv (approximately 30% of cells were positive for SFvIN#33 expression), selection of the SV40-treated SupT1 cells for transgene expression in culture was not required to achieve very high rates of transduction. Finally, SV40 transduction did not slow the rate of cell proliferation significantly. Cell recovery, tested by counting of trypan blue-negative cells, was comparable in SV40-treated and MLV-treated cultures (data not shown). Thus, SV40 transduction was not demonstrably toxic to these cells. cells, compared to the same SFv delivered by MLV-SFVIN#33. HIV-1 challenge studies were performed using virus strain NL . Control SupT1 cells were untreated, or treated with SV(HBS). It is of note that cell growth curves and viability of SupT1 cells were unaltered by transduction with either of these SV40-derived vectors, as described above. The infectivity assays were performed with transduced, mixed SupT1 cell populations. For comparison, MLV-SFvIN#33-transduced, selected SupT1 cells were challenged in parallel.
For HIV-1 challenge experiments, unselected and uncloned SFvIN#33-transduced SupT1 cells, HBSAg SupT1 cells and non-transduced SupT1 cells were treated with two different doses of HIV-1 NL4-3 (0.05 pg/ml and 0.5 pg/ml of p24 antigen equivalents). Replication of HIV-1 in these cultures was evaluated by quantifying the levels of HIV-1 p24 antigen released into the culture medium (Figure 4 
Figure 5 Anti-IN SFv inhibition of cytopathic effects of HIV-1 infection. The microscopic morphology (syncytium formation and cell death) of SupT1 cells infected with syncytium-inducing strain HIV-1 NL4-3 (0.5 pg/ml) after 15 days after infection is shown. (a) SupT1 non-transduced cells; (b) mixed cell populations expressing HBsAg; (c) mixed cell populations transduced with SV(Aw) and expressing anti-IN SFv.
All photomicrographs are ×400.
Discussion
We have previously reported that anti-IN SFv#33 significantly inhibited HIV-1 replication, when delivered to SupT1 cells using a retroviral vector, followed by selection for SFv-expressing cells. We now report that anti-IN SFv#33 delivery, using SV40 as a transduction vehicle, is equally effective as MLV SFvIN#33 in protecting SupT1 cells from HIV-1 infection and that this delivery system has the distinct advantage that its effectiveness does not require selection for transgene-expressing cells before challenge with HIV-1. SV40 was chosen as a delivery vehicle to compare with MLV in these studies for several reasons. SV40 infects virtually all mammalian nucleated cell types, and high titer SV40-derived gene transfer vectors are stable and are easily produced, with expression of SV40-delivered transgenes persisting for long periods in vivo. 4, 5 Also, a single transduction treatment of normal human or simian bone marrow progenitor cells results in long-term carriage of the transgene, most likely via integration (DS Strayer et al, preliminary observations). SV40 also transduces resting and dividing cells with about equal efficiency: unstimulated peripheral blood mononuclear cells are easily transduced ex vivo, as are hepatocytes, neurons and other non-cycling cells in vivo, 5, 6 (M Zern and D Strayer, in preparation; R Chowdhury and D Strayer, in preparation). This is of importance, as nonactivated T-lymphocytes and non-proliferating monocyte/macrophages are critical cellular reservoirs for HIV-1 in vivo.
The SV40-derived constructs applied to these studies are replication-incompetent in cells that lack SV40 Tag. 4 In addition, the viral large T antigen is the major target of the immune system in eliminating cells infected with wild-type (wt) SV40, [31] [32] [33] [34] [35] suggesting that Tag-deleted, replication-defective SV40-derivative viruses should be minimally immunogenic. We have confirmed this hypothesis: such vectors can be administered to normal, immunocompetent animals many times but do not elicit detectable neutralizing antibody versus SV40. 30 The combination of lack of immunogenicity and high levels of durable transduction efficiency of SV40 for bone marrow-derived cells, suggested that this virus might deliver anti-HIV-1 gene therapeutics effectively. To test this possibility, we developed a recombinant SV40 vector to deliver the SFvIN#33, which had already been shown to inhibit HIV-1 infection when it was delivered by MLV. 20 Cytoplasmic SFvIN#33 blocks HIV-1 infection somewhat more efficiently than a nucleus-targeted SFvIN#33. 20 Our current immunostaining results suggest that the SFvIN#33 localizes predominantly in the cytoplasm. Using SV40 to express the anti-IN SFv#33 did not affect the localization of the protein, which is still cytoplasmic. In this report, we demonstrate that intracellular expression of an anti-HIV-1 IN-SFv decreases HIV-1 replication in T-lymphocytic cells. This finding is significant in that it suggests a new and previously unexplored avenue in attempts to inhibit HIV-1 replication before integration of viral DNA into the host genome.
Transduction using onco-retroviral vectors has certain limitations. Firstly, one must often select the cells expressing the gene of interest by using a neomycinresistance gene (neo r ). Secondly, although they may vary in host cell range depending on how they are packaged, oncoretroviruses usually infect a limited range of cells and these cells must be dividing at the time of infection. Finally, the efficiency of transduction with MLV vectors in our hands is relatively low. In contrast, SV40 infects a wide range of cells and has a very high transduction efficiency. Our results show that Ͼ90% of cells treated with SV(Aw) express anti-IN SFv#33 after transduction and continued culture. This is an advantage that could be very useful for transduction of primary cells. It has been reported that SV40 can infect such cells as hematopoietic and peripheral blood mononuclear cells (PBMC). 5, 36 The authors in the former report used the SV40-based pseudoviral system for transfer of the human MDR1 gene. Highly efficient gene transfer into several important cell types, including fresh unmanipulated primary human bone marrow cells and PBMC, was shown. 5, 36 We have also found high efficiency gene transfer to bone marrow-derived cells using SV40, as described above (DS Strayer et al, in preparation).
Of importance, most if not all anti-HIV-1 gene therapeutics can be overwhelmed by utilizing relatively high challenge MOIs dramatically in vitro. This observation was repeated in our studies: SFvIN#33 delivered by both SV40 and MLV was highly effective in inhibiting HIV-1 at challenge 0.05 pg/ml of p24 antigen, but did not dramatically alter the course of HIV-1 infection at challenge 0.5 pg/ml of p24 antigen. This finding may be problematic for inhibiting HIV-1 in the interstices of lymphatic tissues of infected individuals, where HIV-1 concentrations may be higher than those inhibited by the therapeutic approaches described here. 37 In such cases, multiple simultaneous therapeutic modalities or multiple administrations may be necessary to provide effective protection.
The ability to deliver functional anti-HIV-1 SFv-IN, using SV40 as vector represents a novel and potentially useful technology that could contribute to the efficient inhibition of HIV-1 replication. The high efficiency of SV40 transduction, the lack of need for selection, the ability of SV40 to transduce a wide range of target cells and the potential for multiple administrations in vivo, all combine with the effectiveness of SFvIN#33 delivery by SV40 demonstrated here, to suggest that SV40-delivered anti-retroviral gene therapy represents a potentially useful new class of anti-retroviral agents. This concept could also further assist in analyzing the molecular events within the lentiviral life cycle.
Materials and methods
Plasmids and viral expression constructs The HIV-1 molecular clone used in this study was pNL . This strain was obtained from the AIDS Reagent Repository (NIH). HIV-1 NL4-3 is T-tropic viral strain with highly cytopathic effects.
The construct, MLV vector containing anti-IN #33 (pSLXCMV-SFvIN#33), has been described previously. 20 The IN#33 SFv binds to the non-specific DNA binding site in HIV-1 IN, and strongly inhibits HIV-1 replication in transduced human T-lymphocytic cells.
Construction of recombinant SV40 derivative viruses for gene transfer has been described previously in principle. 4 The recombinant SV40-derived virus, SV(Aw), was made similarly and will be described briefly. The wildtype (wt) SV40 genome cloned into pBR322 was provided as plasmid pBSV-1 from Janet Butel (Baylor College of Medicine). The large T antigen gene was excised from this plasmid and replaced by a polylinker. Into this polylinker, an expression construct containing cytomegalovirus intermediate-early promoter (CMV-IEP) plus the cDNA for SFvIN#33 was cloned, to yield pBSV(CMV)Aw.
The control virus used for these studies was SV(HBS). The production and characterization of this virus have been reported. 30 Briefly, the gene for hepatitis B surface antigen (HBsAg) was cloned into the Tag-deleted SV40 genome, immediately downstream from two tandem SV40 early promoters. The resulting plasmid was pSV5(HBS).
Production of SV40 derivative viruses
The techniques used in generating viruses from such plasmids as pSV5(HBS) and pBSV(CMV)Aw have been described. 4 Briefly, the virus genome was excised from the carrier plasmid and purified by agarose gel electrophoresis. It was then recircularized and transfected into COS-7 cells, the packaging cell-line used for these studies. No helper virus was used: the COS cells supply the necessary Tag in trans. These virus stocks were prepared as cell lysates. After initial virus preparations were made in this fashion, expanded stocks were prepared by infecting COS-7 cells with virus from the original preparation. Further transfections are not done. Resulting viruses are replication incompetent. 4 Virus stocks are titered by in situ PCR as described previously. 38 This provides for direct enumeration of infectious units in a preparation.
Cell cultures
The COS-7 packaging cell line was maintained in Dulbecco's modified Eagle's medium (DMEM) + 10% fetal calf serum (FCS, Hyclone, Logan, UT, USA). The same culture conditions were used for 293T. SupT1, a CD4+ human T-lymphocyte cell line susceptible to HIV-1 infection, was grown in RPMI-1640 medium + 10% FCS. 4 All the cells were grown at 37°C in humidified incubator with 5% CO 2 .
HIV-1 viral stocks 293T cells were transfected by a standard calcium-phosphate method (Promega, Madison, WI, USA). 1 × 10 6 293T cells were plated in 10 cm dishes, transfected with 10 mg of pNL 4-3 DNA and then incubated in DMEM containing 10% FCS (growth medium) for 7 h. The medium was then removed and replaced with fresh DMEM growth medium + 10% FCS. Virus-containing supernatants were collected at 48 h. The quantity of virus present in transfected cell supernatants was determined by measuring HIV-1 p24 antigen levels, using an enzyme-linked immunosorbant assay (ELISA) (Cellular Products). Viral stocks were assayed for their infectious titers on CEM T-cells, and these data were used to calculate MOI in each experiment.
Transduction of T-lymphocytic cells
Procedures for infecting SupT1 cells with MuLVSFvIN#33, and for selecting transgene-expressing transduced cells, have been reported elsewhere in detail. 20 For transduction using SV40-derived vectors, SupT1 cells were treated with SV(Aw), carrying the cDNA for SFvIN#33, or SV(HBS), carrying the gene for hepatitis B surface antigen (HBsAg) for 24 h at an MOI of 10. This step was repeated twice, but at MOI of 3, on sequential days. No selection was used. The SV40-treated SupT1 cells were then cultured for 2 weeks.
HIV-1 challenge
The mixed populations of HIV-1-susceptible T-cells (SupT1) which expressed the SFvIN#33 and HBSAg proteins were maintained in RPMI-1640 + 10% FCS for at least 2 weeks before HIV-1 infection. Parental SupT1 cells alone and cells expressing the SFvIN#33 and HBSAg proteins, were incubated with infectious cell-free HIV-1 NL4-3 overnight. The cells were washed with prewarmed, serum-free medium and then maintained in growth medium. Every 3 days, cells were split 1:2 to maintain a cell density of approximately 10 6 /ml and the culture supernatants were collected for HIV-1 p24 antigen analyses. The HIV-1 p24 antigen levels in supernatants were determined by ELISA. Cell viability was monitored by trypan blue exclusion.
Immunostaining for protein expression Subcellular localization of intracellularly expressed SFvIN#33 protein within the cells was determined by indirect immunofluorescence assays. Infected SupT1 cells were cultured after infection with SV40 on eight-chambered glass slides overnight. Cells were then fixed with methanol at room temperature for 10 min and blocked overnight with 1% phosphate-buffered saline/bovine serum albumin (PBS/BSA). The slides were treated overnight with a 1:200 dilution of goat anti-mouse polyclonal IgG (Nordic Immunology, Tilburg, The Netherlands). After several washings, cells were incubated with a 1:64 dilution of fluorescein isothiocyanate (FITC)-labeled rabbit anti-goat IgG (Sigma, St Louis, MO, USA) for 1 h at 37°C. After washing five times in PBS, cells were mounted and analyzed by epiflurorescence microscopy.
Detection of SFvIN#33 protein by Western blot analysis
Cells (10 6 ), which had been transduced with MLV or SV40 vectors carrying the SFvIN#33 expression construct, were lysed with lysis buffer (100 mm Tris pH 8.0, 100 mm NaCl, 0.5% NP-40, 1 mm PMSF, 10 mg/ml leupeptin, 2 mg/ml aprotinin, 10 mg/ml pepstatin). Protein lysate was loaded on a 12% SDS-polyacrylamide gel, electrophoresed and blotted to a PVDF membrane (Schleicher and Schuell, Keene, NH, USA). The membrane was blocked with 5% skim milk for 2 h, treated with goat polyclonal anti-mouse IgG overnight at 4°C, and then with horseradish peroxidase (HRP)-conjugated rabbit anti-goat IgG antibody for 2 h at room temperature. Signal was detected using chemiluminescence reagent (DuPont NEN, Wilmington, DE, USA).
